Microbubble Drug Conjugates for Targeted Gene Therapy Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering biologics and viral gene therapies across the blood-brain barrier (BBB) are invasive, inefficient, and often result in systemic adverse effects, limiting their effectiveness for treating central nervous system (CNS) disorders.
Innovation Solution
The development of microbubble drug conjugates (MDCs) with antibody linkers that bind to and neutralize viral vectors, allowing for non-invasive, targeted delivery of viral gene therapies using focused ultrasound to open the BBB, while preventing transduction and permanent genetic changes in healthy tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If invasive methods are used to deliver biologics and viral gene therapies across the blood-brain barrier, then delivery effectiveness is improved, but patient safety and ease of operation deteriorate
Solution Approach 1:
The patent uses microbubble drug conjugates as intermediary carriers that can cross the blood-brain barrier. The microbubbles serve as vehicles to transport biologics and viral gene therapies across the BBB without requiring invasive surgical procedures, thus maintaining delivery effectiveness while eliminating invasiveness
Solution Approach 2:
The patent replaces mechanical invasive delivery systems (such as surgical injections or catheters) with acoustic field-based delivery using focused ultrasound. The ultrasound waves interact with microbubbles to facilitate drug delivery across the BBB in a non-invasive manner, substituting mechanical invasion with acoustic field interaction
2Productivity
If high-dose viral gene therapies are delivered to treat CNS disorders, then treatment efficacy is improved, but systemic adverse effects worsen
Solution Approach 1:
The patent applies local quality by using antibody linkers with specific binding affinity to target viral vectors to particular locations (diseased brain regions) rather than distributing them systemically. This ensures high-dose therapy is concentrated only where needed, maintaining treatment efficacy while minimizing systemic adverse effects
Solution Approach 2:
The microbubble drug conjugate acts as a targeted intermediary that delivers viral gene therapies specifically to diseased regions. The antibody linkers on the microbubble surface bind to viral vectors and guide them to the target location, preventing systemic distribution and associated adverse effects
3Ease of operation
If viral gene therapies are delivered to open the BBB, then treatment accessibility is improved, but permanent genetic changes in healthy tissues worsen
Solution Approach 1:
The patent employs dynamic control through focused ultrasound parameters that can be adjusted to temporarily open the BBB without causing permanent damage. The acoustic field intensity and duration can be optimized to achieve transient BBB permeability for drug delivery while avoiding permanent genetic changes in healthy tissues
Solution Approach 2:
The microbubble drug conjugate serves as a controlled intermediary that facilitates temporary BBB opening. The microbubbles respond dynamically to ultrasound fields, enabling reversible BBB permeabilization that allows drug delivery without causing permanent genetic modifications to healthy brain tissue
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise, high-dose delivery of viral gene therapies to diseased brain regions, enhancing treatment efficacy while minimizing systemic adverse effects and avoiding permanent genetic changes.
Implementation Method 1
antibodies with binding specificity to different viral vectors (AAV2, AAV9, adenovirus, etc.) covalently conjugated to the lipids that form the microbubble shells
Implementation Method 2
viral vector antibody linkers that also neutralize the viral vectors in order to limit transduction
Implementation Method 3
Focused ultrasound can be used to target diseased regions of the body and release biologic drugs or viral gene therapy from MDCs for local delivery
Implementation Method 4
the appropriate targeting biologic can allow for the delivery of more microbubbles to the diseased area, thus improving the therapeutic effect. This is achieved by bursting the microbubbles in the body to open cellular barriers via sonoporation effects
Implementation Method 5
When ultrasound is applied to microbubbles circulating in the body, they oscillate and reflect the ultrasound waves resulting in contrast enhancement relative to the surrounding tissue
Implementation Method 6
Ultrasound can induce rapid expansion and contraction of microbubbles to mechanically impact tumor vasculature in order to slow or halt tumor blood flow
Data Source
AI summary
The present invention relates to methods of producing microbubble drug conjugates, viral gene therapy microbubble drug conjugates, and disease-targeting microbubbles, for clinical and preclinical ultrasound-mediated therapeutic and diagnostic applications. It includes methods to produce viral vector gene therapy microbubble drug conjugates with antibody linkers conjugated to lipid shelled microbubbles that both bind to and neutralize viral vectors such that the viral gene therapy can transduce and effect permanent genetic changes only after ultrasound is used to disassociate the viral gene therapy from microbubbles at diseased regions of the body.